Merck & Co Inc (MRK)

65.86
0.57 0.87
NYSE : Health Care
Prev Close 65.29
Open 65.52
Day Low/High 65.34 / 66.11
52 Wk Low/High 49.63 / 65.87
Volume 6.80M
Avg Volume 11.10M
Exchange NYSE
Shares Outstanding 2.76B
Market Cap 180.54B
EPS 0.30
P/E Ratio 33.41
Div & Yield 1.88 (2.90%)

Latest News

Cramer: Is the Market Playing 'The Price Is Wrong'?

Cramer: Is the Market Playing 'The Price Is Wrong'?

These may be uncharted waters, but they're not necessarily expensive.

Cramer: Buyers for Bristol-Myers Are Few and Far Between

Cramer: Buyers for Bristol-Myers Are Few and Far Between

Icahn may have a tough time finding interest in this behemoth.

Four Women Match Men Sitting on the Most S&P 500 Boards

Four Women Match Men Sitting on the Most S&P 500 Boards

More than a dozen people sit on the four boards for components of the S&P 500, of which four are women.

Bristol-Myers Buys Back Shares, Shuffles Board

Bristol-Myers Buys Back Shares, Shuffles Board

The drug company will carry out 80% of a $2B repurchase by Feb. 28 after pressure from insurgent Jana Partners. Icahn also reportedly acquired a stake, with focus on M&A.

Execs from Boeing, Pfizer Send Letter Backing House GOP Tax Plan

Execs from Boeing, Pfizer Send Letter Backing House GOP Tax Plan

Executives from 16 companies, including Boeing, Oracle and Pfizer, are weighing in to support the increasingly-contentious border adjustment tax

Clovis, Tesaro Soar on Astrazeneca Phase Three News

Clovis, Tesaro Soar on Astrazeneca Phase Three News

AstraZeneca shares, meanwhile, were less-than-moved by the news.

Health Care ETF Has Been Ailing

Health Care ETF Has Been Ailing

You might want to review your holdings in the sector.

Http://www.ilumhealthsolutions.com

Http://www.ilumhealthsolutions.com

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the launch of ILÚM Health Solutions, which provides enterprise-wide disease management tools and services to enable improved outcomes...

Snapchat's Parent Prices IPO at Low End of Expectations

Snapchat's Parent Prices IPO at Low End of Expectations

Snap Inc. is preparing for the biggest technology IPO since Alibaba in 2014.

DexCom Is a Great Healthcare Stock to Buy Now

DexCom Is a Great Healthcare Stock to Buy Now

The continuous glucose monitor maker is an excellent growth opportunity.

Eli Lilly Is Great Stock to Buy Now

Eli Lilly Is Great Stock to Buy Now

Here's why the pharmaceutical company is a solid addition to your portfolio.

Analysts' Actions -- Acorda, Restoration Hardware, Humana, Merck and More

Analysts' Actions -- Acorda, Restoration Hardware, Humana, Merck and More

Here are Wednesday's top research calls, including upgrades for Acorda and Restoration Hardware, a price target increase for Humana and a price target cut for Merck.

Merck Alzheimer's Drug Study Halted Early for Futility

Merck Alzheimer's Drug Study Halted Early for Futility

Independent study monitors concluded that there was "virtually no chance of finding a positive clinical effect."

Merck Announces EPOCH Study Of Verubecestat For The Treatment Of People With Mild To Moderate Alzheimer's Disease To Stop For Lack Of Efficacy

Merck Announces EPOCH Study Of Verubecestat For The Treatment Of People With Mild To Moderate Alzheimer's Disease To Stop For Lack Of Efficacy

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that it will be stopping protocol 017, also known as the EPOCH study, a Phase 2/3 study evaluating verubecestat, an investigational small...

Merck's Doravirine, An Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) For The Treatment Of HIV-1 Infection, Met Primary Efficacy Endpoint In Pivotal Phase 3 Trial

Merck's Doravirine, An Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) For The Treatment Of HIV-1 Infection, Met Primary Efficacy Endpoint In Pivotal Phase 3 Trial

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results of a pivotal Phase 3 clinical trial evaluating the safety and efficacy of doravirine (MK-1439), an investigational non-nucleoside...

Merck Becomes #26 Most Shorted Dow Stock, Replacing Goldman Sachs Group

Merck Becomes #26 Most Shorted Dow Stock, Replacing Goldman Sachs Group

The most recent short interest data has been released for the 01/31/2017 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Cramer: Here's the Reason for Allergan's Remarkable Run

Cramer: Here's the Reason for Allergan's Remarkable Run

Static doesn't work in this industry. Pipelines work.

Merck Foundation Announces Six Program Grant Recipients For Alliance To Advance Patient-Centered Cancer Care

Merck Foundation Announces Six Program Grant Recipients For Alliance To Advance Patient-Centered Cancer Care

The Merck Foundation (Foundation), announced today the selection of the six program sites and National Program Office forming the Alliance to Advance Patient-Centered Cancer Care (the Alliance).

Cramer: Here's the Reason for Allergan's Remarkable Run

Cramer: Here's the Reason for Allergan's Remarkable Run

Static doesn't work in this industry. Pipelines work.

Biotech Tesaro Climbs on Takeout Reports

Biotech Tesaro Climbs on Takeout Reports

The company's shares were up 14% on rumors that it is working with investment banks to consider a sale.

Cramer: Allergan Is the New Pharma Growth Stock

Cramer: Allergan Is the New Pharma Growth Stock

Jim Cramer compares Allergan's growth to other pharma stocks.

Streamlined FDA Approval Process Would Boost Drug Makers

Streamlined FDA Approval Process Would Boost Drug Makers

Would get drugs to market faster and possibly more cheaply.

Novice Trade: AbbVie

Novice Trade: AbbVie

Getting FDA to streamline its approval process would boost drug makers.

Pfizer CEO: 'Misinformation About Drug Pricing Is Far Greater Than I've Ever Seen'

Pfizer CEO: 'Misinformation About Drug Pricing Is Far Greater Than I've Ever Seen'

The pharma giant will lever up should a strategic deal opportunity come along, too.

Facebook Falls, Merck and Philip Morris Rise on Earnings Releases

Facebook Falls, Merck and Philip Morris Rise on Earnings Releases

Here is the scoop on three of Thursday's biggest movers.

House Panel to Take Up Trump's Call to Speed FDA Approvals

House Panel to Take Up Trump's Call to Speed FDA Approvals

Generics for drugs facing shortages or having few manufacturers is bill's focus.

Wall Street's Up and Down Day Mirrors Washington Rollercoaster

Wall Street's Up and Down Day Mirrors Washington Rollercoaster

Stocks see choppy trading on Thursday as Wall Street struggles for direction amid a barrage of news coming from Washington.

TheStreet Quant Rating: B (Buy)